Neuromedin S vs TLQP-21 — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
Neuromedin S (NMS) is a 36-amino acid amidated neuropeptide discovered in 2005 that shares a C-terminal amino acid sequence with neuromedin U (NMU) and activates the same NMUR1 and NMUR2 receptors. However, NMS has a markedly different expression pattern: while NMU is broadly exp...
Calculate Neuromedin S dose →TLQP-21 is a 21-amino acid peptide derived from the C-terminal region of VGF (Nerve Growth Factor-Inducible), a large precursor neuropeptide that is proteolytically cleaved into multiple bioactive fragments. VGF is strongly induced by NGF and BDNF and plays roles in energy homeos...
Calculate TLQP-21 dose →| Parameter | Neuromedin S | TLQP-21 |
|---|---|---|
| Category | Neuropeptide | Neuropeptide |
| Research | Research | Research |
| Half-Life | Short (minutes, estimated) | Unknown |
| Typical Dose | 1-10 nmol (central, animal) | 1-100 nmol (animal) |
| Frequency | Variable | Variable |
| Route | Intracerebroventricular, Subcutaneous | Intrathecal, Subcutaneous, Intracerebroventricular |
| FDA Status | Not approved | Not approved |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.